ADA 2025 Recap: 5 Studies on Obesity to Know

The 2025 American Diabetes Association (ADA) Scientific Sessions held June 20–24 in Chicago showcased the latest trajectory of obesity treatment. While years past have been defined by the arrival and validation of GLP-1 receptor agonists like semaglutide and tirzepatide, this year’s meeting highlighted the next steps, with new studies evaluating broader therapeutic formats, higher-dose strategies, and dual-target combinations designed for sustained efficacy and greater patient flexibility.